GlassScriptPhysician profile
Brent Holt
NPI 1053300558
$6,634.42
in general payments reported to CMS, 2019-2025
33 companies · $666 in 2025
The $666 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,460 · 2020: $558 · 2021: $696 · 2022: $553 · 2023: $885 · 2024: $816 · 2025: $666.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,266 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,266.26 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tosoh Bioscience, INC. | $1,451.00 | 2019 | |
| Novo Nordisk INC | $1,082.59 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $803.48 | 2019-2025 | Repatha, Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $577.09 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $442.74 | 2021-2025 | |
| Astellas Pharma US INC | $314.48 | 2019-2024 | Veozah, Myrbetriq |
| Novartis Pharmaceuticals Corporation | $250.73 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $166.18 | 2019-2023 | Gardasil 9, M-M-R II, Proquad |
| Pfizer INC. | $164.42 | 2019-2025 | |
| Glaxosmithkline, LLC. | $149.15 | 2021-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $147.48 | 2022-2023 | |
| Lilly USA, LLC | $143.87 | 2020-2024 | Mounjaro, Jardiance, Zepbound |
| Janssen Pharmaceuticals, INC | $123.93 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $117.55 | 2019-2021 | |
| Allergan, INC. | $83.23 | 2019-2020 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $63.76 | 2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $57.56 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $57.39 | 2025 | Gemtesa |
| Corcept Therapeutics | $51.47 | 2023 | Korlym |
| Amarin Pharma, INC. | $50.87 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $48.08 | 2019-2020 | |
| Exact Sciences Corporation | $45.93 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33.79 | 2020-2025 | Xifaxan |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $32.60 | 2025 | Caplyta |
| Phathom Pharmaceuticals, INC. | $31.42 | 2025 | Voquezna |
| Biohaven Pharmaceutical Holding Company LTD. | $26.58 | 2022 | |
| Averitas Pharma INC. | $22.39 | 2024 | Qutenza |
| Sanofi Pasteur INC. | $20.99 | 2022 | |
| Shire North American Group INC | $18.58 | 2019 | |
| Sunovion Pharmaceuticals INC. | $14.91 | 2021 | |
| Radius Health, INC. | $13.90 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $13.27 | 2020 | |
| Dexcom, INC. | $13.01 | 2023 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brent Holt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.